Free Trial
NASDAQ:KLDO

Kaleido Biosciences (KLDO) Stock Price, News & Analysis

Kaleido Biosciences logo
$0.0020 +0.00 (+1,900.00%)
As of 05/1/2025 09:30 AM Eastern

About Kaleido Biosciences Stock (NASDAQ:KLDO)

Key Stats

Today's Range
$0.0020
$0.0020
50-Day Range
N/A
52-Week Range
$0.00
$0.07
Volume
265 shs
Average Volume
9,255 shs
Market Capitalization
$85,246.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Stock News Headlines

Kaleido Biosciences Inc (KLDO)
U.S. Stock Market Now on Verge of Collapse
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost 80% of their wealth in real terms. But before you touch any of your holdings – or buy anything – please review my latest warning about the U.S. stock market. It's free to watch.
Kaleido Biosciences (OTC: KLDO)
See More Headlines

KLDO Stock Analysis - Frequently Asked Questions

Kaleido Biosciences' stock was trading at $0.0001 at the beginning of 2025. Since then, KLDO shares have increased by 1,900.0% and is now trading at $0.0020.
View the best growth stocks for 2025 here
.

Kaleido Biosciences, Inc. (NASDAQ:KLDO) issued its quarterly earnings data on Monday, November, 1st. The company reported ($0.54) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.54). The business earned $0.10 million during the quarter, compared to analysts' expectations of $0.25 million.

Kaleido Biosciences (KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kaleido Biosciences investors own include Editas Medicine (EDIT), Enovix (ENVX), COMPASS Pathways (CMPS), Rambus (RMBS), Luminar Technologies (LAZR), Precision BioSciences (DTIL) and Globant (GLOB).

Company Calendar

Last Earnings
11/01/2021
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Computer Software
Current Symbol
NASDAQ:KLDO
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.10 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
38,787,000
Market Cap
$85,246.00
Optionable
Not Optionable
Beta
-0.06
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:KLDO) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners